Revisión

Rasagiline in monotherapy in patients with early stages of Parkinson’s disease and in combined and adjunct therapy to levodopa with moderate and advanced stages

J. Pagonabarraga-Mora, M.C. Rodríguez-Oroz [REV NEUROL 2013;56:25-34] PMID: 23250679 DOI: https://doi.org/10.33588/rn.5601.2012597

OPEN ACCESS

Volumen 56 | Number 01 | Nº of views of the article 9.709 | Nº of PDF downloads 1.254 | Article publication date 01/01/2013

Download PDF Castellano Citation Search in PubMed

Share in:

Go to another issue

ABSTRACT

Rasagiline is effective in the early stages of the disease and has shown a possible effect of modifying disease progression at a dose of 1 mg. The accurate management of dopaminergic drugs in Parkinson’s disease is able to delay the appearance of motor fluctuations and dyskinesias. The combination of different drugs that provide a more continuous dopaminergic stimulation (rasagiline, dopamine agonists) not only exerts a benefit through diminishing the impact of pulsatile stimulation on post-synaptic dopamine receptors, but allows to decrease total daily levodopa requirements. The combination of rasagiline with other dopaminergic drugs has demonstrated to be as efficacious as entacapone for improving both the frequency and severity of motor fluctuations. Likewise, new evidences have shown that the earlier introduction of rasagiline is associated with a delay in introducing other dopaminergic drugs, thus indicating that the symptomatic benefit of rasagiline on daily motor function is not only present in the early Parkinson’s disease stages, but is maintained over time. KeywordsAdvanced stages Continuous dopaminergic stimulation Early stages Motor fluctuations Parkinson’s disease Rasagiline CategoriesNeurodegeneración Trastornos del movimiento

FULL TEXT (solo disponible en lengua castellana / Only available in Spanish)

Acceso directo al último número

Último Podcast

Revisión

Rasagiline in monotherapy in patients with early stages of Parkinson’s disease and in combined and adjunct therapy to levodopa with moderate and advanced stages

¡CONVIÉRTASE EN USUARIO PREMIUM DE NEUROLOGIA.COM!

Al hacerse premium, está apoyándonos para que Revista de Neurología siga siendo uno de los referentes de habla hispana en la difusión del conocimiento en neurociencias. ¡Gratuita tanto para autores como para todos los usuarios de la web!